http://www.annals.org/cgi/content/full/146/11/816
In this issue, Nishimura and colleagues review the value of testing for anti–cyclic citrullinated peptide (CCP) antibodies in the diagnosis of rheumatoid arthritis (1). Their well-done meta-analysis confirms that the presence of anti-CCP antibody is more specific than rheumatoid factor for diagnosing rheumatoid arthritis and thereby corroborates the results of 2 published systematic reviews (2, 3).